Bortot Barbara, Apollonio Maura, Baj Gabriele, Andolfi Laura, Zupin Luisa, Crovella Sergio, di Giosia Matteo, Cantelli Andrea, Saporetti Roberto, Ulfo Luca, Petrosino Annapaola, Di Lorenzo Giovanni, Romano Federico, Ricci Giuseppe, Mongiat Maurizio, Danielli Alberto, Calvaresi Matteo, Biffi Stefania
Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy.
BRAIN Center for Neuroscience, Department of Life Sciences, University of Trieste, Trieste, Italy.
Free Radic Biol Med. 2022 Feb 1;179:242-251. doi: 10.1016/j.freeradbiomed.2021.11.019. Epub 2021 Nov 19.
Photodynamic therapy (PDT) is a potential synergistic approach to chemotherapy for treating ovarian cancer, the most lethal gynecologic malignancy. Here we used M13 bacteriophage as a targeted vector for the efficient photodynamic killing of SKOV3 and COV362 cells. The M13 phage was refactored (M13) to display an EGFR binding peptide in its tip that is frequently overexpressed in ovarian cancer. The refactored phage was conjugated with chlorin e6 (Ce6), one of the most widely used photosensitizers (M13-Ce6). The new platform, upon irradiation, generated ROS by type I mechanism and showed activity in killing SKOV3 and COV362 cells even at concentrations in which Ce6 alone was ineffective. A microscopy analysis demonstrated an enhanced cellular uptake of M13-Ce6 compared to free Ce6 and its mitochondrial localization. Western blot analysis revealed significant downregulation in the expression of EGFR in cells exposed to M13-Ce6 after PDT. Following PDT treatment, autophagy induction was supported by an increased expression of LC3II, along with a raised autophagic fluorescent signal, as observed by fluorescence microscopy analysis for autophagosome visualization. As a conclusion we have herein proposed a bacteriophage-based receptor targeted photodynamic therapy for EGFR-positive ovarian cancer.
光动力疗法(PDT)是一种用于治疗卵巢癌(最致命的妇科恶性肿瘤)的潜在化疗协同方法。在此,我们使用M13噬菌体作为靶向载体,以有效光动力杀伤SKOV3和COV362细胞。对M13噬菌体进行改造(M13),使其在尖端展示一种在卵巢癌中经常过度表达的表皮生长因子受体(EGFR)结合肽。将改造后的噬菌体与二氢卟吩e6(Ce6,最广泛使用的光敏剂之一)偶联(M13-Ce6)。这个新平台在照射后通过I型机制产生活性氧(ROS),并且即使在单独使用Ce6无效的浓度下,也显示出对SKOV3和COV362细胞的杀伤活性。显微镜分析表明,与游离Ce6相比,M13-Ce6的细胞摄取增加,并且其定位于线粒体。蛋白质印迹分析显示,光动力疗法后暴露于M13-Ce6的细胞中EGFR表达显著下调。光动力疗法治疗后,通过自噬相关蛋白轻链3-II(LC3II)表达增加以及自噬荧光信号增强支持自噬诱导,这通过用于自噬体可视化的荧光显微镜分析观察到。总之,我们在此提出了一种基于噬菌体的、针对EGFR阳性卵巢癌的受体靶向光动力疗法。